慢性乙型肝炎-话题@MedSci

#慢性乙型肝炎#

119篇内容 | 4211人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2179922, encodeId=b4df21e9922ae, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a> <a href='/topic/show?id=acff109e2987' target=_blank style='color:#2F92EE;'>#selgantolimod#</a>, objectTitle=J Hepatol：口服TLR8激动剂selgantolimod治疗病毒抑制的慢性乙型肝炎患者的安全性和有效性, objectType=article, longId=808593, objectId=f361808593d5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016434455_4754896.png, objectUrl=/article/show_article.do?id=f361808593d5, replyNumber=0, likeNumber=83, createdTime=2024-01-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f361808593d5, moduleTitle=J Hepatol：口服TLR8激动剂selgantolimod治疗病毒抑制的慢性乙型肝炎患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f361808593d5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2116819, encodeId=c9012116819ad, content=这个研究对中国有现实意义，因为中国合并<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>的人很多。合并的<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>再激活率为2.0%，这个比例也不小了，值得重视。不过分析发现，<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>(RTX)、<a href='/topic/show?id=60ba9e805ae' target=_blank style='color:#2F92EE;'>#阿巴西普#</a>以及<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)抑制剂的<a href='/topic/show?id=fdd01053199b' target=_blank style='color:#2F92EE;'>#HBV再激活率#</a>为9.0%，6.0% ，1.0%，0.0%，0.0%。总体而言，JAK抑制剂是安全的，当然<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>等更安全, objectTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, objectType=article, longId=761107, objectId=9106e611071d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024114319_4754896.jpeg, objectUrl=/article/show_article.do?id=9106e611071d, replyNumber=0, likeNumber=156, createdTime=2023-02-28, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9106e611071d, moduleTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9106e611071d)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1271332, encodeId=e80712e133201, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=慢性乙型肝炎病毒感染的自然病程特征, objectType=article, longId=737468, objectId=86a3e37468fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86a3e37468fc, replyNumber=0, likeNumber=114, createdTime=2022-09-02, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86a3e37468fc, moduleTitle=慢性乙型肝炎病毒感染的自然病程特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86a3e37468fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271331, encodeId=20b912e1331a7, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=APT：核苷(酸)类似物治疗的慢性乙型肝炎患者改用替诺福韦酯治疗, objectType=article, longId=737349, objectId=e0cfe37349f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0cfe37349f4, replyNumber=0, likeNumber=112, createdTime=2022-08-31, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0cfe37349f4, moduleTitle=APT：核苷(酸)类似物治疗的慢性乙型肝炎患者改用替诺福韦酯治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0cfe37349f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271330, encodeId=2a7e12e133031, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Front Immunol ：干扰素α-2a治疗HBeAg阳性慢性乙型肝炎过程中细胞因子和病毒学标志物的动态变化, objectType=article, longId=736351, objectId=9244e3635169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9244e3635169, replyNumber=0, likeNumber=118, createdTime=2022-08-21, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9244e3635169, moduleTitle=Front Immunol ：干扰素α-2a治疗HBeAg阳性慢性乙型肝炎过程中细胞因子和病毒学标志物的动态变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9244e3635169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271329, encodeId=d32c12e13291b, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Front Immunol：孕期抗病毒治疗对慢性乙型肝炎孕妇自然杀伤细胞的影响, objectType=article, longId=730663, objectId=b600e30663c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b600e30663c0, replyNumber=0, likeNumber=143, createdTime=2022-06-29, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b600e30663c0, moduleTitle=Front Immunol：孕期抗病毒治疗对慢性乙型肝炎孕妇自然杀伤细胞的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b600e30663c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271328, encodeId=7d9212e132890, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=AJG: 阿司匹林与慢性乙型肝炎中肝癌风险降低相关, objectType=article, longId=730072, objectId=c5cbe300723b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5cbe300723b, replyNumber=0, likeNumber=117, createdTime=2022-06-22, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5cbe300723b, moduleTitle=AJG: 阿司匹林与慢性乙型肝炎中肝癌风险降低相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5cbe300723b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271327, encodeId=e73512e13271c, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响, objectType=article, longId=728103, objectId=4b08e2810361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b08e2810361, replyNumber=0, likeNumber=95, createdTime=2022-05-30, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b08e2810361, moduleTitle=CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b08e2810361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271326, encodeId=710712e132692, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=J Gastroenterology：血清可溶性程序性死亡1(sPD-1)可预测慢性乙型肝炎的自发HBeAg 血清学清除程度, objectType=article, longId=726137, objectId=82c5e2613787, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c5e2613787, replyNumber=0, likeNumber=102, createdTime=2022-05-06, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c5e2613787, moduleTitle=J Gastroenterology：血清可溶性程序性死亡1(sPD-1)可预测慢性乙型肝炎的自发HBeAg 血清学清除程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c5e2613787)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271325, encodeId=a2d912e1325e4, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Dig Dis Sci:自发性HBsAg血清学清除与慢性乙型肝炎患者的较低肝纤维化有关, objectType=article, longId=724928, objectId=8a71e249284f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a71e249284f, replyNumber=0, likeNumber=104, createdTime=2022-04-26, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a71e249284f, moduleTitle=Dig Dis Sci:自发性HBsAg血清学清除与慢性乙型肝炎患者的较低肝纤维化有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a71e249284f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271324, encodeId=5ee412e1324b9, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=BMC Gastroenterol：Graves病与慢性乙型肝炎、甲巯咪唑所致肝损伤及自身免疫性肝炎重叠1例, objectType=article, longId=299557, objectId=33e129955e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e129955e79, replyNumber=0, likeNumber=91, createdTime=2022-02-25, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e129955e79, moduleTitle=BMC Gastroenterol：Graves病与慢性乙型肝炎、甲巯咪唑所致肝损伤及自身免疫性肝炎重叠1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e129955e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271323, encodeId=367812e1323fd, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见, objectType=article, longId=295415, objectId=c67e2954154b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67e2954154b, replyNumber=0, likeNumber=88, createdTime=2022-02-12, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67e2954154b, moduleTitle=指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c67e2954154b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271322, encodeId=66bc12e13227f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险, objectType=article, longId=292069, objectId=157e29206907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=157e29206907, replyNumber=0, likeNumber=108, createdTime=2021-12-18, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=157e29206907, moduleTitle=Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=157e29206907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271321, encodeId=ac6f12e1321b1, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=指南推荐《国内外慢性乙型肝炎管理指南推荐建议的比较》, objectType=article, longId=221704, objectId=9096221e043c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9096221e043c, replyNumber=0, likeNumber=88, createdTime=2021-12-10, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9096221e043c, moduleTitle=指南推荐《国内外慢性乙型肝炎管理指南推荐建议的比较》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9096221e043c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271320, encodeId=94c612e132094, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读, objectType=article, longId=221447, objectId=481522144ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481522144ecd, replyNumber=0, likeNumber=111, createdTime=2021-12-04, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481522144ecd, moduleTitle=《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481522144ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271319, encodeId=a47012e1319d5, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？, objectType=article, longId=220827, objectId=3d7222082e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7222082e46, replyNumber=0, likeNumber=97, createdTime=2021-11-24, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7222082e46, moduleTitle=Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7222082e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271318, encodeId=0b6112e131857, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Nat Med：反义寡核苷酸bepirovirsen治疗慢性乙型肝炎疗效, objectType=article, longId=218657, objectId=970f21865eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970f21865eac, replyNumber=0, likeNumber=121, createdTime=2021-10-17, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970f21865eac, moduleTitle=Nat Med：反义寡核苷酸bepirovirsen治疗慢性乙型肝炎疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970f21865eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271317, encodeId=68f112e131775, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B, objectType=article, longId=218649, objectId=b92d2186494a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b92d2186494a, replyNumber=0, likeNumber=89, createdTime=2021-10-17, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b92d2186494a, moduleTitle=J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b92d2186494a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271316, encodeId=b96a12e1316c1, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响, objectType=article, longId=217119, objectId=e86e21e119cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e86e21e119cf, replyNumber=0, likeNumber=109, createdTime=2021-09-16, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e86e21e119cf, moduleTitle=Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e86e21e119cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271315, encodeId=d35f12e1315fb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, objectTitle=ENYO Pharma发布进行中的两项Vonafexor (EYP001)治疗慢性乙型肝炎患者2a期研究16周顶线中期结果, objectType=article, longId=215346, objectId=4dff215346ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dff215346ac, replyNumber=0, likeNumber=84, createdTime=2021-08-07, rootId=0, userName=guguangxiang, userId=e11f100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dff215346ac, moduleTitle=ENYO Pharma发布进行中的两项Vonafexor (EYP001)治疗慢性乙型肝炎患者2a期研究16周顶线中期结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dff215346ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

慢性乙型肝炎

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性乙型肝炎# #selgantolimod#

J Hepatol：口服TLR8激动剂selgantolimod治疗病毒抑制的慢性乙型肝炎患者的安全性和有效性

2024-01-08发表于上海

showtest (审核中...)

前往app查看评论内容

全文收起这个研究对中国有现实意义，因为中国合并#慢性乙型肝炎#的人很多。合并的#HBV#再激活率为2.0%，这个比例也不小了，值得重视。不过分析发现，#利妥昔单抗#(RTX)、#阿巴西普#以及#JAK抑制剂#、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)抑制剂的#HBV再激活率#为9.0%，6.0% ，1.0%，0.0%，0.0%。总体而言，JAK抑制剂是安全的，当然#托珠单抗#等更安全

Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险

2023-02-28发表于上海

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

慢性乙型肝炎病毒感染的自然病程特征

2022-09-02

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

APT：核苷(酸)类似物治疗的慢性乙型肝炎患者改用替诺福韦酯治疗

2022-08-31

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Front Immunol ：干扰素α-2a治疗HBeAg阳性慢性乙型肝炎过程中细胞因子和病毒学标志物的动态变化

2022-08-21

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Front Immunol：孕期抗病毒治疗对慢性乙型肝炎孕妇自然杀伤细胞的影响

2022-06-29

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

AJG: 阿司匹林与慢性乙型肝炎中肝癌风险降低相关

2022-06-22

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

CGH: HBeAg阳性不会对慢性乙型肝炎患者口服抗病毒治疗期间肝细胞癌风险产生影响

2022-05-30

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

J Gastroenterology：血清可溶性程序性死亡1(sPD-1)可预测慢性乙型肝炎的自发HBeAg 血清学清除程度

2022-05-06

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Dig Dis Sci:自发性HBsAg血清学清除与慢性乙型肝炎患者的较低肝纤维化有关

2022-04-26

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

BMC Gastroenterol：Graves病与慢性乙型肝炎、甲巯咪唑所致肝损伤及自身免疫性肝炎重叠1例

2022-02-25

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见

2022-02-12

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Int J Cancer：慢性乙型肝炎病毒(HBV)感染可增加某些胃肠道(GI)肿瘤的发病风险

2021-12-18

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

指南推荐《国内外慢性乙型肝炎管理指南推荐建议的比较》

2021-12-10

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读

2021-12-04

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？

2021-11-24

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Nat Med：反义寡核苷酸bepirovirsen治疗慢性乙型肝炎疗效

2021-10-17

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

J Hepatol：一种预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险的人工智能模型：PLAN-B

2021-10-17

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

Clin Gastroenterology H: HBeAg 对慢性乙型肝炎患者口服抗病毒药物治疗期间肝细胞癌风险的影响

2021-09-16

guguangxiang (审核中...)

前往app查看评论内容

#慢性乙型肝炎#

ENYO Pharma发布进行中的两项Vonafexor (EYP001)治疗慢性乙型肝炎患者2a期研究16周顶线中期结果

2021-08-07

科室
- - 订阅+
  - 更多科室
工具
服务